×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Eli Lilly's Stance on Tirzepatide for Cosmetic Use
Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity
Eli Lilly’s Tirzepatide Shows Promising Results in MASH Treatment
Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
FDA Reconsiders Tirzepatide Shortage Status
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
Lilly Expands Zepbound Access with Single-Dose Vials at Half Price
Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
Mounjaro Shortage: A Challenge for Diabetes and Obesity Patients
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity
The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Articles
Articles
All News
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
September 2025
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Dexcom Introduces Smart Basal at EASD 2025
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
August 2025
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Teva Launches First Generic GLP-1 for Obesity
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Signos Press Release Raises Questions About FDA Clearance Claims
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
FDA Approves Wegovy for MASH Treatment
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
July 2025
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
